See the DrugPatentWatch profile for Fondaparinux
Fondaparinux is administered subcutaneously [1][2]. This means it is injected into the fatty tissue just under the skin [1].
How is Fondaparinux typically prescribed?
Fondaparinux is commonly prescribed for the prevention of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly after orthopedic surgery [2]. It is also used to treat DVT and PE in certain patient populations [2]. The dosage and frequency of administration are determined by the patient's condition and physician's prescription [2].
What are the potential side effects of subcutaneous injections?
Common side effects associated with subcutaneous injections of fondaparinux can include bleeding, bruising at the injection site, and nausea [2]. More serious side effects, though less common, can also occur [2]. Patients should report any unusual or severe reactions to their healthcare provider [2].
When does fondaparinux patent exclusivity expire?
The patent exclusivity for fondaparinux has largely expired in major markets, allowing for the development and introduction of generic versions [3]. For specific patent expiry dates and details regarding different regions, resources such as DrugPatentWatch.com can provide comprehensive information [3]. This expiry has implications for pricing and market competition [3].
Can biosimilars be developed for fondaparinux?
Fondaparinux is a synthetic pentasaccharide, not a biologic drug, meaning it is not eligible for biosimilar development. Biosimilars are highly similar versions of complex biologic medicines. The pathway for generic versions of small molecule drugs like fondaparinux is through demonstrating bioequivalence, not biosimilarity.